logo
Share SHARE
FONT-SIZE Plus   Neg

Cleveland BioLabs (CBLI) Has Surged To An 8-Month High

Cleveland BioLabs (CBLI) gapped up at the open Monday and has risen sharply in early trade on the highest volume of the year. Shares are now up 0.83 at $2.39. The stock has surged to an 8-month high.

Cleveland BioLabs announced this morning that the European Medicines Agency has accepted its pediatric investigation plan for entolimod as a medical radiation countermeasure.

The FDA has also finished its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA has consented to the initiation of an in vivo biocomparability study of these formulations in non-human primates.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT